Ability to dose TERN-701 without regard to food represents a key potential differentiator within the allosteric BCR-ABL inhibitor class Pharmacokinetic data show no clinically significant difference...
FOSTER CITY, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (€œTerns€ or the €œCompany€) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
Terns Pharma Reports Fourth Quarter and Full Year 2023 Financial Results
Terns Pharmaceuticals Announces Orphan Drug Designation Granted to TERN-701
Terns Reports Inducement Grant to Employee Under Nasdaq Listing Rule 5635(C)(4)
FOSTER CITY, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (œTerns or the œCompany) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
FOSTER CITY, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (Terns or the Company) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
FOSTER CITY, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (Terns or the Company) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
Terns Reports Inducement Grant to Employee Under Nasdaq Listing Rule 5635(C)(4)
Terns Pharmaceuticals is bowing to competitive pressure and walking away from a liver disease that has long been without meaningful treatment options—until now.